Transcranial Photobiomodulation in Anxiety Disorders
ConditionSymptoms of Anxiety
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorFrancisco Gonzalez-Lima, PhD
About this trial
The investigators have previously shown that safe, non-invasive methods of brain stimulation such as the administration of transcranial infrared light can result in improvements to cognition and emotion. The investigators hypothesize that transcranial photobiomodulation (tPBM) can be used in conjunction with attention bias assessment and modification to reduce anxiety symptoms in individuals with sub-clinical anxiety.
Eligibility criteria
Qualifiers
18 years of age and older
State-Trait Anxiety Index (STAI) questionnaire score between 40-59 (indicates moderate sub-clinical anxiety)
Patient Health Questionnaire (PHQ-9) score between 1-9 (indicates minimal to mild sub-clinical depression)
Disqualifiers
STAI score less than 40 or greater than 59
PHQ-9 score greater than 9
Medication instability (i.e., medication change within 6 weeks)
Indicated suicidal ideation
Trial design
Treatments tested in this trial
- Attention bias assessment and modification
- Transcranial photobiomodulation
Treatment groups
280 Participants
are divided into 4 treatment groupsSponsors and collaborators
Francisco Gonzalez-Lima, PhD
Lead sponsor
University of Texas at Austin
Sponsor institution
Source ClinicalTrials.gov